1. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Issue 2 (February 2017) Authors: Konstan, Michael W; McKone, Edward F; Moss, Richard B; Marigowda, Gautham; Tian, Simon; Waltz, David; Huang, Xiaohong; Lubarsky, Barry; Rubin, Jaime; Millar, Stefanie J; Pasta, David J; Mayer-Hamblett, Nicole; Goss, Christopher H; Morgan, Wayne; Sawicki, Gregory S Journal: Lancet Issue: Volume 5:Issue 2(2017) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Closing the loop between wearable technology and human biology: a new paradigm for steering neuromuscular form and function. (22nd February 2021) Authors: Sartori, Massimo; Sawicki, Gregory S Journal: Progress in biomedical engineering Issue: Volume 3:Number 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Issue 8 (10th May 2018) Authors: Bessonova, Leona; Volkova, Nataliya; Higgins, Mark; Bengtsson, Leif; Tian, Simon; Simard, Christopher; Konstan, Michael W; Sawicki, Gregory S; Sewall, Ase; Nyangoma, Stephen; Elbert, Alexander; Marshall, Bruce C; Bilton, Diana Journal: Thorax Issue: Volume 73:Issue 8(2018) Page Start: 731 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Issue 4 (April 2023) Authors: Mayer-Hamblett, Nicole; Ratjen, Felix; Russell, Renee; Donaldson, Scott H; Riekert, Kristin A; Sawicki, Gregory S; Odem-Davis, Katherine; Young, Julia K; Rosenbluth, Daniel; Taylor-Cousar, Jennifer L; Goss, Christopher H; Retsch-Bogart, George; Clancy, John Paul; Genatossio, Alan; O'Sullivan, Bri... Journal: Lancet Issue: Volume 11:Issue 4(2023) Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Erratum: More is not always better: modeling the effects of elastic exoskeleton compliance on underlying ankle muscle–tendon dynamics (2014 Bioinspir. Biomim.9 046018). (5th January 2015) Authors: Robertson, Benjamin D; Farris, Dominic J; Sawicki, Gregory S Journal: Bioinspiration & biomimetics Issue: Volume 10:Number 1(2015:Feb.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Hurry Up and Get Out of the Way! Exploring the Limits of Muscle-Based Latch Systems for Power Amplification. (16th August 2019) Authors: Abbott, Emily M; Nezwek, Teron; Schmitt, Daniel; Sawicki, Gregory S Journal: Integrative and comparative biology Issue: Volume 59:Number 6(2019:Dec.) Page Start: 1546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Issue 7 (July 2021) Authors: Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Ne... Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Issue 2 (February 2016) Authors: Davies, Jane C; Cunningham, Steve; Harris, William T; Lapey, Allen; Regelmann, Warren E; Sawicki, Gregory S; Southern, Kevin W; Robertson, Sarah; Green, Yulia; Cooke, Jon; Rosenfeld, Margaret Journal: Lancet Issue: Volume 4:Issue 2(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Issue 4 (April 2019) Authors: McNamara, John J; McColley, Susanna A; Marigowda, Gautham; Liu, Fang; Tian, Simon; Owen, Caroline A; Stiles, David; Li, Chonghua; Waltz, David; Wang, Linda T; Sawicki, Gregory S Journal: Lancet Issue: Volume 7:Issue 4(2019) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Transition Readiness Not Associated With Measures of Health in Youth With IBD. Issue 1 (1st January 2021) Authors: Arvanitis, Marina; Hart, Laura C; DeWalt, Darren A; Díaz-González de Ferris, Maria E; Sawicki, Gregory S; Long, Millie D; Martin, Christopher F; Kappelman, Michael D Journal: Inflammatory bowel diseases Issue: Volume 27:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗